Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Three-Dimensional Rotational Angiography-Guided Stent Placement for Treatment of Acquired Supravalvar Aortic Stenosis
Anderson, Jason H. , Fetterly, Kenneth A. , Taggart, Nathaniel W. , Taggart, Nathaniel W , Anderson, Jason

Circulation | August 3, 2015 | Volume: 132 | Issue: 5 | Pages: 455-456

10.1161/circulationaha.115.017612 | PMID 26240266 Get It

Diagnosis of Free-Wall Rupture by Left Ventricular Angiogram After Inferior ST-Segment–Elevation Myocardial Infarction
Reddy, Yogesh N.V. , Al‐Hijji, Mohammed , Best, Patricia J.M. , Sinak, Lawrence J., Suri, Rakesh M. , Ijioma, Nkechinyere , Aberle, Sara J., Goyal, Deepi G. , Best, Patricia J., Ijioma, Nkechinyere N, Singh, Mandeep , Al-Hijji, Mohammed A , Nishimura, Rick , Ijioma, Nkechi

Circulation | August 3, 2015 | Volume: 132 | Issue: 5 | Pages: No page available

10.1161/circulationaha.115.015951 | PMID 26240267 Get It

Response to Letter Regarding Article “Impact of Annual Operator and Institutional Volume on Percutaneous Coronary Intervention Outcomes: A 5-Year United States Experience (2005–2009)”
Badheka, Apurva O., Patel, Nileshkumar, Grover, Peeyush , Singh, Vikas , Patel, Nilay , Arora, Shilpkumar , Chothani, Ankit , Mehta, Kathan , Deshmukh, Abhishek , Savani, Ghanshyambhai T., Patel, Achint , Panaich, Sidakpal , Shah, Neeraj , Brown, Michael, Mohamad, Tamam , Makkar, Raj , Schreiber, Theodore , Rihal, Charanjit S. , Cohen, Mauricio G. , Rathod, Ankit D. , Grines, Cindy L. , Rihal, Charanjit S. , Panaich, Sidakpal S , Cohen, Mauricio G

Circulation | August 3, 2015 | Volume: 132 | Issue: 5 | Pages: No page available

10.1161/circulationaha.115.015221 | PMID 26240270 Get It

Performance of Cystatin C– and Creatinine-Based Estimated Glomerular Filtration Rate Equations Depends on Patient Characteristics
Meeusen, Jeffrey W. , Voskoboev, Nikolay, Baumann, N, Rule, Andrew D. , Lieske, John C.

Clinical Chemistry | August 3, 2015 | Volume: 61 | Issue: 10 | Pages: 1265-1272

10.1373/clinchem.2015.243030 | PMID 26240296 Get It

Abstract BACKGROUND The Kidney Disease Improving Global Outcomes (KDIGO) guideline recommends use of a cystatin C–based estimated glomerular filtration rate (eGFR) to confirm creatinine-based eGFR between 45 and 59 mL · min−1 · (1.73 m2)−1. Prior studies have demonstrated that comorbidities such as solid-organ transplant strongly influence the relationship between measured GFR, creatinine, and cystatin C. Our objective was to evaluate the performance of cystatin C–based eGFR equations compared with creatinine-based eGFR and measured GFR across different clinical presentations. METHODS We compared the performance of the CKD-EPI 2009 creatinine-based estimated GFR equation (eGFRCr) and the newer CKD-EPI 2012 cystatin C–based equations (eGFRCys and eGFRCr-Cys) with measured GFR (iothalamate renal clearance) across defined patient populations. Patients (n = 1652) were categorized as transplant recipients (n = 568 kidney; n = 319 other organ), known chronic kidney disease (CKD) patients (n = 618), or potential kidney donors (n = 147). RESULTS eGFRCr-Cys showed the most consistent performance across different clinical populations. Among potential kidney donors without CKD [stage 2 or higher; eGFR >60 mL · min−1 · (1.73 m2)−1], eGFRCys and eGFRCr-Cys demonstrated significantly less bias than eGFRCr; however, all 3 equations substantially underestimated GFR when eGFR was <60 mL · min−1 · (1.73 m2)−1. Among transplant recipients with CKD stage 3B or greater [eGFR <45 mL · min−1 · (1.73 m2)−1], eGFRCys was significantly more biased than eGFRCr. No clear differences in eGFR bias between equations were observed among known CKD patients regardless of eGFR range or in any patient group with a GFR between 45 and 59 mL · min−1 · (1.73 m2)−1. CONCLUSIONS The performance of eGFR equations depends on patient characteristics that are readily apparent on presentation. Among the 3 CKD-EPI equations, eGFRCr-Cys performed most consistently across the studied patient populations.
Ehrlichia Meningitis Mimicking Aneurysmal Subarachnoid Hemorrhage
Dredla, Brynn K., Dredla, Brynn, Freeman, William D.

The Neurohospitalist | August 3, 2015 | Volume: 6 | Issue: 2 | Pages: 76-79

10.1177/1941874415596743 | PMID 27053985 Get It

Thunderclap headache is a sudden and severe headache that can occur after an aneurysmal subarachnoid hemorrhage (SAH). Subarachnoid hemorrhage is a medical emergency that requires prompt attention and hospitalization. Patients with thunderclap headache often undergo a noncontrast head computed tomography (CT) scan to ascertain SAH bleeding and, if the scan is negative, then undergo a lumbar puncture to look for cerebrospinal fluid (CSF) red blood cells (RBCs), which would be consistent with an aneurysmal leak. If the initial CT is negative and CSF is positive for RBCs, patients are usually admitted to the hospital for evaluation of intracranial aneurysm. We encountered a patient with thunderclap headache whose initial head CT was negative for SAH and whose CSF tested positive for RBCs. The patient was referred to our center for evaluation and management of aneurysmal SAH. However, on careful review of the patient’s medical history, serum laboratory values, and spinal fluid values, the patient was diagnosed with Ehrlichia chaffeensis meningitis. While Ehrlichia meningitis is rare, it is important to recognize the clinical clues that could help avoid formal cerebral angiography, a costly and potentially unnecessary procedure. We present how this case represented a cognitive framing bias and anchoring heuristic as well as steps that medical providers can use to prevent such cognitive errors in diagnosis.
American Board of Internal Medicine and Maintenance of Certification Standards—Reply
Holmboe, Eric S. , Cook, David A.

JAMA Internal Medicine | August 3, 2015 | Volume: 175 | Issue: 8 | Pages: 1425

10.1001/jamainternmed.2015.1115 | PMID 26236981 Get It

Faculty Opinions recommendation of The prodrug DHED selectively delivers 17β-estradiol to the brain for treating estrogen-responsive disorders.
Miller, Virginia M.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 3, 2015 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725668060.793508469 Get It

A Case of P-Wave Mimicry
Ray, Jordan , Goldschlager, Nora , Ray, Jordan C., Kusumoto, Fred

JAMA Internal Medicine | August 3, 2015 | Volume: 175 | Issue: 10 | Pages: 1693

10.1001/jamainternmed.2015.3342 | PMID 26237750 Get It

New Investigator and Trainee Task Force Survey on the Recruitment and Retention of Headache Specialists
Monteith, Tesha, Strauss, Lauren , Starling, Amaal J. , Monteith, Teshamae , Starling, Amaal, Minen, Mia T. , Monteith, Teshamae S

Headache: The Journal of Head and Face Pain | August 3, 2015 | Volume: 55 | Issue: 8 | Pages: 1092-1101

10.1111/head.12623 | PMID 26234315 Get It

Objectives We sought to survey the N ew I nvestigators and T rainees S ection ( NITS ) members of the A merican H eadache S ociety ( AHS ) to better understand their exposure to headache medicine during training and to determine their perceptions and attitudes about the field and the future of headache medicine. Background Despite the high prevalence of headache disorders in the general population, only about 2% of neurology residents pursue headache medicine fellowships. Furthermore, there is a paucity of U nited C ouncil of N eurologic S ubspecialties headache specialists in the country to meet the population demands. Thus, there needs to be a focus on how to recruit and retain more headache specialists. Methods A survey was distributed via S urvey M onkey to the NITS listserv. It remained online for 60 days, during which reminder emails were sent to members of the listserv. In addition, the survey was available on laptops at NITS ‐related events at an annual AHS meeting. Descriptive analyses were then conducted using S urvey M onkey and E xcel. Results Of the 93 members of NITS , 64 of the 96 (68.8%) clicked to initiate the survey and 52.7% successfully completed it. Attendings made up the majority of respondents (62.5%), followed by fellows (10.9%), and residents (7.8%). Key highlights of the survey included the following: just under 10% reported no exposure to a headache center during any time in their training (medical school, residency, or fellowship); less than 2% had exposure to a headache center during medical school; less than half of participants reported exposure to a headache center in residency (45.3%) and during fellowship (43.4%). Having a mentor in the field, liking the patient population, and working in a headache center, 64.7%, 52.9%, and 41.2%, respectively, were the top ways in which participants became interested in headache. The journal H eadache (56.9%), attendings (56.3%), and the AHS / A merican A cademy of N eurology guidelines for migraine management (52.0%) are the resources cited as being used all/most of the time. About 82.4% strongly agree that there needs to be improved headache education for physicians of all specialties (primary care, emergency department, psychiatry); 84.4% feel that they are appreciated by their patients; 68.6% feel that there is strong support in their departments for headache; 56.9% believe that their work schedule leaves enough time for personal and family life; and 60.8% agreed that their professional life will improve in years to come. Participants agreed/strongly agreed that they like to treat the following diseases/symptoms: migraine headache (98.0%), cluster headache (92%), chronic daily headache (84%), and post‐concussive syndrome (71.4%). Participants disagreed/strongly disagreed that they like to treat the following comorbid conditions/symptoms: low back pain (66.6%), dizziness (42.9%), sleep apnea (36.7%), depression (32.0%), and anxiety (32.0%). Conclusions In this detailed survey on the recruitment and retention of headache specialists, the following themes emerged: mentorship and exposure to a headache center are key foundations in the young investigator/trainee experience. Young headache specialists appear positive about their field of medicine. These specialists like to treat various headache types but not necessarily some of the related comorbidities (sleep disorders, depression, anxiety, back pain, and dizziness). Finally, there was strong agreement that there needs to be improved headache education for physicians of other medical specialties.
Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation
Nei, Scott D., Wittwer, Erica D. , Frazee, Erin N., Nei, Scott D., Kashani, Kianoush , Frazee, Erin N.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | August 3, 2015 | Volume: 35 | Issue: 8 | Pages: No page available

10.1002/phar.1615 | PMID 26242293 Get It

Levetiracetam is a first‐line therapy for seizures in critically ill patients because of its clinical efficacy, minimal drug interactions, and wide therapeutic window. The primary mechanism of levetiracetam clearance is renal, and the drug has a low molecular weight. It is hydrophilic and exhibits minimal protein binding. Thus it is expected that levetiracetam will be removed by continuous venovenous hemofiltration (CVVH), with limited clearance by venoarterial extracorporeal membrane oxygenation (ECMO). We describe the case of a 67‐year‐old man who was admitted to the cardiovascular surgery intensive care unit after cardiac arrest and initiation of venoarterial ECMO. His course was complicated by multiorgan dysfunction including acute renal failure requiring CVVH. On hospital day 6, intravenous levetiracetam, at a loading dose of 2000 mg followed by a maintenance dose of 1000 mg every 12 hours, was initiated for new‐onset seizures. The volume of distribution was 0.65 L/kg, and clearance was measured with peak (ranging from 26.5–39.8 μg/ml) and trough (ranging from 13.9–18.2 μg/ml) concentrations. Elimination half‐life ranged from 8.7–10.1 hours. Renal dysfunction reduces levetiracetam clearance, and dosage reductions are recommended to prevent accumulation. Current CVVH dosing recommendations are based on predicted removal without clinical data. The volume of distribution and clearance in this case were similar to those of a normal healthy patient. Based on these results, we recommend considering an initial levetiracetam dose of 1000 mg every 12 hours for patients receiving CVVH, with dosage adjustments based on therapeutic drug monitoring.